Philip Smith, Ph.D.
Vice Department Chair, Division of Pharmacoengineering and Molecular Pharmaceutics
Administrative Director, Division of Pharmacoengineering and Molecular Pharmaceutics
Associate Professor, Division of Pharmacoengineering and Molecular Pharmaceutics
1309 Kerr Hall, , CB# 7571, Chapel Hill, NC, 27599-7571
Dr. Smith received a B.S. in Pharmacy from the University of Illinois, Chicago Medical Center, and then a Ph.D. in Pharmaceutical Chemistry, with an emphasis in pharmacokinetics, in 1985 from the University of California, San Francisco. After postdoctoral studies at the National Institutes of Health in Bethesda, MD, as a National Research Council Fellow, he joined the faculty of the College of Pharmacy at the University of Texas at Austin. In 1992 he moved to the School of Pharmacy at the University of North Carolina at Chapel where he is presently Associate Professor in the Division of Pharmacoengineering and Molecular Pharmaceutics. Dr. Smith’s main research efforts are directed toward establishing quantitative methods for proteins associated with drug disposition, understanding factors influencing the disposition, pharmacokinetics, reactivity and potential toxicity of labile acyl glucuronide metabolites, the role of glucuronidation in intestinal toxicity of drugs and the modulation of drug glucuronidation by botanicals/herbal remedies. He is Director of the Quantitative Targeted Proteomics Laboratory which utilizes LC-MS for protein measurements in complex matrices. He was recently on the USP Dietary Supplements: Performance Standards Expert Committee. He is past recipient of the Faculty Development Award in Pharmacology and Toxicology from the PhRMA Foundation. Dr. Smith was Co-Chair of the 1997 ISSX meeting and is currently an ISSX Council Member for North America. He serves as an ad hoc reviewer for NIH study sections and as a consultant to the pharmaceutical industry. Dr. Smith is a member of the editorial advisory board for the Journal of Pharmacology and Experimental Therapeutics, Current Drug Metabolism, and participates as a reviewer for the journals Drug Metabolism and Disposition, Biochemical Pharmacology, Pharmaceutical Research, the Journal of Pharmaceutical Sciences and others.
- Lilly QTAP of Transporter Proteins in Hepatocytes of Five Species
- Lilly QTAP of Transporter Proteins in KO Mice and Rats
- Lilly QTAP of UGTs/P450/CES/Transporters in Intestinal Microsomes and Hepatocytes
- Quantitative Targeted Proteomic Analysis (QTAP) of Human Microsomes for ADME Screening
- Regulation of Hepatic P450s by anti-Cholesterol Drugs
- Targeted Quantitative Proteomics Analysis of Transporters, including OAT2/7 in Human Hepatocytes